{"nctId":"NCT01852812","briefTitle":"Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)","startDateStruct":{"date":"2013-06-07","type":"ACTUAL"},"conditions":["Perennial Allergic Rhinitis"],"count":87,"armGroups":[{"label":"Montelukast 4 mg OG/1-5 year olds","type":"EXPERIMENTAL","interventionNames":["Drug: Montelukast Oral Granules (OG)"]},{"label":"Montelukast 5 mg CT/6-9 year olds","type":"EXPERIMENTAL","interventionNames":["Drug: Montelukast Chewable Tablets (CT)"]},{"label":"Montelukast 5 mg CT/10-15 year olds","type":"EXPERIMENTAL","interventionNames":["Drug: Montelukast Chewable Tablets (CT)"]}],"interventions":[{"name":"Montelukast Oral Granules (OG)","otherNames":[]},{"name":"Montelukast Chewable Tablets (CT)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Weight ≥8 kg\n* Diagnosis of PAR and has symptoms of PAR at Visit 1\n\nExclusion Criteria:\n\n* Past or present medical history of asthma\n* Diagosis of acute rhinitis, simple rhinitis, rhinitis congestive, rhinitis atrophic, sinusitis with purulent nasal discharge, rhinitis medicamentosa or nonallergic rhinitis (e.g. vasomotor rhinitis, eosinophilic rhinitis)\n* Started hyposensitization therapy or non-specific immunotherapy within 6 months prior to Visit 1\n* Medical history of inferior concha mucosal resection, submucous resection of inferior turbinates or other surgery aimed at reduction and/or modulation of nasal mucosa (including electrocoagulation, cryoextraction or application of trichloroacetic acid)\n* Clinically significant, active disease of the cardiovascular or hematologic systems or uncontrolled hypertension (1 to 5 year olds: \\>120/70 mmHg; 6 to 9 year olds: \\>130/80 mmHg; 10 to 15 year olds: \\>140/85 mmHg)\n* Medical history of stunted growth\n* Serious drug allergy\n* Treated with other clinical study drug within 3 months prior to Visit 1","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"15 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Experience at Least One Adverse Event (AE)","description":"An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a pre-existing condition that is temporally associated with the use of study drug is also an AE. Participants were monitored for the occurrence of AEs for up to 14 days after last dose of study drug (up to a total of 14 weeks). AEs were reported based on the dose of study drug participants received.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5","spread":null},{"groupId":"OG001","value":"55.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Discontinue Study Drug Due to an AE","description":"An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a pre-existing condition that is temporally associated with the use of study drug is also an AE. Discontinuations due to an AE were reported based on the dose of study drug participants received.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Area Under the Time-Concentration Curve (AUC 0-∞) of Montelukast CT and Montelukast OG","description":"Blood samples for pharmacokinetic (PK) assessments were collected at either 1 hour (h) or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4300","spread":"800"},{"groupId":"OG001","value":"4350","spread":"760"},{"groupId":"OG002","value":"3500","spread":"620"}]}]}]},{"type":"PRIMARY","title":"Maximum Plasma Concentration (Cmax) of Montelukast CT and Montelukast OG","description":"Blood samples for PK assessments were collected at either 1 h or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"510","spread":"84"},{"groupId":"OG001","value":"438","spread":"82"},{"groupId":"OG002","value":"344","spread":"61"}]}]}]},{"type":"PRIMARY","title":"Time to Cmax (Tmax) of Montelukast CT and Montelukast OG","description":"Blood samples for PK assessments were collected at either 1 h or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.74","spread":"0.60"},{"groupId":"OG001","value":"3.55","spread":"0.71"},{"groupId":"OG002","value":"3.65","spread":"0.60"}]}]}]},{"type":"PRIMARY","title":"Apparent Elimination Half-life (t1/2) of Montelukast CT and Montelukast OG","description":"Blood samples for PK assessments were collected at either 1 h or 3 h post-dose on Day 1 and at either 14 h or 22 h post-dose on Day 28.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.27","spread":"0.56"},{"groupId":"OG001","value":"2.01","spread":"0.75"},{"groupId":"OG002","value":"2.08","spread":"0.66"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":51},"commonTop":["Nasopharyngitis","Pharyngitis","Acute sinusitis","Bronchitis","Otitis media"]}}}